Interferon alpha in the therapy of CML.
This paper summarizes the experience with interferon alpha (IFN alpha) as single-agent therapy and in combination gathered at M.D. Anderson Cancer Center. It also covers some of the laboratory research associated with these clinical studies.
Talpaz
M
M
Department of Clinical Immunology and Biological Therapy, University of Texas Cancer Center, M.D. Anderson Hospital, Houston.
Kantarjian
H
H
Kurzrock
R
R
Gutterman
J U
JU
D003131:Combined Modality Therapy; D003561:Cytarabine / Q000627:therapeutic use; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000628:therapy*; D011994:Recombinant Proteins
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D003561:Cytarabine; D007371:Interferon-gamma